Meningococcal Polysaccharide A O-Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years

OA  Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue CVI About CVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Com...

Full description

Saved in:
Bibliographic Details
Published inClinical and Vaccine Immunology Vol. 20; no. 10; pp. 1499 - 1507
Main Authors Lupisan, Socorro, Limkittikul, Kriengsak, Sosa, Nestor, Chanthavanich, Pornthep, Bianco, Véronique, Baine, Yaela, Van der Wielen, Marie, Miller, Jacqueline M.
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.10.2013
Subjects
Acetylation
Adolescent
Adult
Blood Bactericidal Activity
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - pathology
Fatigue
Fatigue - epidemiology
Female
Headache - epidemiology
Healthy Volunteers
Humans
Male
Meningococcal Vaccines - administration & dosage
Meningococcal Vaccines - adverse effects
Meningococcal Vaccines - immunology
Neisseria meningitidis
Pain - epidemiology
Polysaccharides, Bacterial - immunology
Polysaccharides, Bacterial - metabolism
Vaccines
Vaccines, Conjugate - administration & dosage
Vaccines, Conjugate - adverse effects
Vaccines, Conjugate - immunology
Young Adult
Online AccessGet full text
ISSN1556-6811
1556-679X
1556-679X
DOI10.1128/CVI.00162-13

Cover

Abstract OA  Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue CVI About CVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy CVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 1556-6811 Online ISSN: 1556-679X Copyright © 2014 by the American Society for Microbiology.   For an alternate route to CVI .asm.org, visit: CVI       
AbstractList In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A polysaccharide (PS) O-acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY polysaccharide vaccine (Men-PS). In this phase III, partially blinded, controlled study, 1,170 healthy subjects aged 18 to 25 years were randomized (1:1:1) to receive one dose of MenACWY-TT lot A (ACWY-A) (68% O-acetylation), MenACWY-TT lot B (ACWY-B) (92% O-acetylation), or Men-PS (82% O-acetylation). Immunogenicity was evaluated in terms of serum bactericidal activity using rabbit complement (i.e., rabbit serum bactericidal activity [rSBA]). Solicited symptoms, unsolicited adverse events (AEs), and serious AEs (SAEs) were recorded. The immunogenicities, in terms of rSBA geometric mean titers, were comparable for both lots of MenACWY-TT. The vaccine response rates across the serogroups were 79.1 to 97.0% in the two ACWY groups and 73.7 to 94.1% in the Men-PS group. All subjects achieved rSBA titers of ≥1:8 for all serogroups. All subjects in the two ACWY groups and 99.5 to 100% in the Men-PS group achieved rSBA titers of ≥1:128. Pain was the most common solicited local symptom and was reported more frequently in the ACWY group (53.9 to 54.7%) than in the Men-PS group (36.8%). The most common solicited general symptoms were fatigue and headache, which were reported by 28.6 to 30.3% and 26.9 to 31.0% of subjects, respectively. Two subjects reported SAEs; one SAE was considered to be related to vaccination (blighted ovum; ACWY-B group). The level of serogroup A PS O-acetylation did not affect vaccine immunogenicity. MenACWY-TT (lot A) was not inferior to Men-PS in terms of vaccine response and was well tolerated.
OA  Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue CVI About CVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy CVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 1556-6811 Online ISSN: 1556-679X Copyright © 2014 by the American Society for Microbiology.   For an alternate route to CVI .asm.org, visit: CVI       
In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A polysaccharide (PS) O -acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY polysaccharide vaccine (Men-PS). In this phase III, partially blinded, controlled study, 1,170 healthy subjects aged 18 to 25 years were randomized (1:1:1) to receive one dose of MenACWY-TT lot A (ACWY-A) (68% O -acetylation), MenACWY-TT lot B (ACWY-B) (92% O -acetylation), or Men-PS (82% O -acetylation). Immunogenicity was evaluated in terms of serum bactericidal activity using rabbit complement (i.e., rabbit serum bactericidal activity [rSBA]). Solicited symptoms, unsolicited adverse events (AEs), and serious AEs (SAEs) were recorded. The immunogenicities, in terms of rSBA geometric mean titers, were comparable for both lots of MenACWY-TT. The vaccine response rates across the serogroups were 79.1 to 97.0% in the two ACWY groups and 73.7 to 94.1% in the Men-PS group. All subjects achieved rSBA titers of ≥1:8 for all serogroups. All subjects in the two ACWY groups and 99.5 to 100% in the Men-PS group achieved rSBA titers of ≥1:128. Pain was the most common solicited local symptom and was reported more frequently in the ACWY group (53.9 to 54.7%) than in the Men-PS group (36.8%). The most common solicited general symptoms were fatigue and headache, which were reported by 28.6 to 30.3% and 26.9 to 31.0% of subjects, respectively. Two subjects reported SAEs; one SAE was considered to be related to vaccination (blighted ovum; ACWY-B group). The level of serogroup A PS O -acetylation did not affect vaccine immunogenicity. MenACWY-TT (lot A) was not inferior to Men-PS in terms of vaccine response and was well tolerated.
In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A polysaccharide (PS) O-acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY polysaccharide vaccine (Men-PS). In this phase III, partially blinded, controlled study, 1,170 healthy subjects aged 18 to 25 years were randomized (1:1:1) to receive one dose of MenACWY-TT lot A (ACWY-A) (68% O-acetylation), MenACWY-TT lot B (ACWY-B) (92% O-acetylation), or Men-PS (82% O-acetylation). Immunogenicity was evaluated in terms of serum bactericidal activity using rabbit complement (i.e., rabbit serum bactericidal activity [rSBA]). Solicited symptoms, unsolicited adverse events (AEs), and serious AEs (SAEs) were recorded. The immunogenicities, in terms of rSBA geometric mean titers, were comparable for both lots of MenACWY-TT. The vaccine response rates across the serogroups were 79.1 to 97.0% in the two ACWY groups and 73.7 to 94.1% in the Men-PS group. All subjects achieved rSBA titers of ≥1:8 for all serogroups. All subjects in the two ACWY groups and 99.5 to 100% in the Men-PS group achieved rSBA titers of ≥1:128. Pain was the most common solicited local symptom and was reported more frequently in the ACWY group (53.9 to 54.7%) than in the Men-PS group (36.8%). The most common solicited general symptoms were fatigue and headache, which were reported by 28.6 to 30.3% and 26.9 to 31.0% of subjects, respectively. Two subjects reported SAEs; one SAE was considered to be related to vaccination (blighted ovum; ACWY-B group). The level of serogroup A PS O-acetylation did not affect vaccine immunogenicity. MenACWY-TT (lot A) was not inferior to Men-PS in terms of vaccine response and was well tolerated.In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A polysaccharide (PS) O-acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY polysaccharide vaccine (Men-PS). In this phase III, partially blinded, controlled study, 1,170 healthy subjects aged 18 to 25 years were randomized (1:1:1) to receive one dose of MenACWY-TT lot A (ACWY-A) (68% O-acetylation), MenACWY-TT lot B (ACWY-B) (92% O-acetylation), or Men-PS (82% O-acetylation). Immunogenicity was evaluated in terms of serum bactericidal activity using rabbit complement (i.e., rabbit serum bactericidal activity [rSBA]). Solicited symptoms, unsolicited adverse events (AEs), and serious AEs (SAEs) were recorded. The immunogenicities, in terms of rSBA geometric mean titers, were comparable for both lots of MenACWY-TT. The vaccine response rates across the serogroups were 79.1 to 97.0% in the two ACWY groups and 73.7 to 94.1% in the Men-PS group. All subjects achieved rSBA titers of ≥1:8 for all serogroups. All subjects in the two ACWY groups and 99.5 to 100% in the Men-PS group achieved rSBA titers of ≥1:128. Pain was the most common solicited local symptom and was reported more frequently in the ACWY group (53.9 to 54.7%) than in the Men-PS group (36.8%). The most common solicited general symptoms were fatigue and headache, which were reported by 28.6 to 30.3% and 26.9 to 31.0% of subjects, respectively. Two subjects reported SAEs; one SAE was considered to be related to vaccination (blighted ovum; ACWY-B group). The level of serogroup A PS O-acetylation did not affect vaccine immunogenicity. MenACWY-TT (lot A) was not inferior to Men-PS in terms of vaccine response and was well tolerated.
In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A polysaccharide (PS) O-acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY polysaccharide vaccine (Men-PS). In this phase III, partially blinded, controlled study, 1,170 healthy subjects aged 18 to 25 years were randomized (1:1:1) to receive one dose of MenACWY-TT lot A (ACWY-A) (68% O-acetylation), MenACWY-TT lot B (ACWY-B) (92% O-acetylation), or Men-PS (82% O-acetylation). Immunogenicity was evaluated in terms of serum bactericidal activity using rabbit complement (i.e., rabbit serum bactericidal activity [rSBA]). Solicited symptoms, unsolicited adverse events (AEs), and serious AEs (SAEs) were recorded. The immunogenicities, in terms of rSBA geometric mean titers, were comparable for both lots of MenACWY-TT. The vaccine response rates across the serogroups were 79.1 to 97.0% in the two ACWY groups and 73.7 to 94.1% in the Men-PS group. All subjects achieved rSBA titers of greater than or equal to 1:8 for all serogroups. All subjects in the two ACWY groups and 99.5 to 100% in the Men-PS group achieved rSBA titers of greater than or equal to 1:128. Pain was the most common solicited local symptom and was reported more frequently in the ACWY group (53.9 to 54.7%) than in the Men-PS group (36.8%). The most common solicited general symptoms were fatigue and headache, which were reported by 28.6 to 30.3% and 26.9 to 31.0% of subjects, respectively. Two subjects reported SAEs; one SAE was considered to be related to vaccination (blighted ovum; ACWY-B group). The level of serogroup A PS O-acetylation did not affect vaccine immunogenicity. MenACWY-TT (lot A) was not inferior to Men-PS in terms of vaccine response and was well tolerated.
Author Pornthep Chanthavanich
Marie Van der Wielen
Kriengsak Limkittikul
Véronique Bianco
Jacqueline M. Miller
Nestor Sosa
Yaela Baine
Socorro Lupisan
Author_xml – sequence: 1
  givenname: Socorro
  surname: Lupisan
  fullname: Lupisan, Socorro
  organization: Research Institute for Tropical Medicine, Department of Health, Muntinlupa City, Philippines
– sequence: 2
  givenname: Kriengsak
  surname: Limkittikul
  fullname: Limkittikul, Kriengsak
  organization: Department of Tropical Paediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
– sequence: 3
  givenname: Nestor
  surname: Sosa
  fullname: Sosa, Nestor
  organization: Pan American Medical Research Center, Panama City, Panama
– sequence: 4
  givenname: Pornthep
  surname: Chanthavanich
  fullname: Chanthavanich, Pornthep
  organization: Department of Tropical Paediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
– sequence: 5
  givenname: Véronique
  surname: Bianco
  fullname: Bianco, Véronique
  organization: GlaxoSmithKline Vaccines, Wavre, Belgium
– sequence: 6
  givenname: Yaela
  surname: Baine
  fullname: Baine, Yaela
  organization: GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania, USA
– sequence: 7
  givenname: Marie
  surname: Van der Wielen
  fullname: Van der Wielen, Marie
  organization: GlaxoSmithKline Vaccines, Wavre, Belgium
– sequence: 8
  givenname: Jacqueline M.
  surname: Miller
  fullname: Miller, Jacqueline M.
  organization: GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23885033$$D View this record in MEDLINE/PubMed
BookMark eNqNkktvEzEUhUeoiD5gxxpZYsOiKfZ4Hg6LSlF4NFKhpZQKVtYd-ybjymOHsacQfjc_ACd9iCIhsfKV_Z17rq_ObrblvMMse8roAWO5eDm9mB1Qyqp8xPiDbIeVZTWq6vGXrdtaMLad7YZwSWnBK1E_yrZzLkRJOd_Jfr1HZ9zCK68UWHLq7SqAUi30RiOZkJPRRGFcWYjGO3KMV2gDee3JBx_JrFuCiiS2mMpucH6ReikTV8TPN7cfB9C9uQKLLpL7RucYwQ2BnPsf3mgy9e5yWEBEcpHcjcNX5AzDYGMg8953BMgZOO078xP1_pqOvbcWNTltIST72Yx8ioPeOB8h2NiuyERv9JNFwpgg0ZO8JF8R-vA4ezgHG_DJzbmXfX775nx6NDo-eTebTo5HqijKOGoKUQs9hrGoldC1hjmMVdUAbRivclGxPBeUUk5VUzfYqLTQdKuQcsCq4prvZYfXfZdD06FWaQ09WLnsTQf9Snow8v6LM61c-CvJBa1zRlODFzcNev9twBBlZ4JCa8GhH4JkRcF5XbGS_wfK61LwMl-jz_4c626e21QkYP8aUL0Pocf5HcKoXIdOptDJTegkW-P5X3gKwSYw6VPG_kv0_FrUmkX73fQoIXRSaWtkTjeSYjzmvwE50OlP
CitedBy_id crossref_primary_10_3390_molecules23061340
crossref_primary_10_1016_j_jadohealth_2018_05_012
crossref_primary_10_1016_j_vaccine_2020_04_005
crossref_primary_10_1586_14760584_2016_1130628
crossref_primary_10_1016_j_phrs_2014_10_006
crossref_primary_10_1016_j_vaccine_2019_07_008
crossref_primary_10_1080_21645515_2016_1143157
crossref_primary_10_1080_21645515_2016_1153206
crossref_primary_10_1038_s41467_020_18464_y
crossref_primary_10_2217_fmb_2018_0343
crossref_primary_10_1016_j_vaccine_2021_09_068
Cites_doi 10.1586/erv.10.3
10.1086/345763
10.1001/archpedi.159.10.907
10.1017/S0950268811000574
10.1086/527401
10.1016/j.ijid.2012.04.006
10.1128/IAI.70.7.3707-3713.2002
10.1093/infdis/136.Supplement.S78
10.1016/j.vaccine.2009.04.063
10.4161/hv.7.2.14068
10.1128/CMR.19.1.142-164.2006
10.1128/JCM.02390-08
10.1097/INF.0b013e3182054ab9
10.1016/j.vaccine.2011.11.051
10.1097/01.inf.0000147642.85129.05
10.1097/INF.0b013e31820e6e02
10.4161/hv.20211
10.1016/j.vaccine.2009.10.104
10.2165/11204790-000000000-00000
10.1086/525260
10.1001/jama.286.6.694
10.1016/j.vaccine.2009.04.061
10.1016/j.vaccine.2009.10.064
10.1016/j.vaccine.2008.08.075
10.1084/jem.129.6.1327
10.1586/14760584.5.6.851
10.1111/j.1574-6976.2006.00051.x
10.1016/S0929-6646(09)60371-5
10.1056/NEJMra0906357
10.1128/CVI.05354-11
10.1586/erv.10.147
10.1007/978-1-61779-346-2_1
10.1371/journal.pone.0044102
10.1016/j.vaccine.2005.01.051
10.1586/14760584.6.4.485
10.1128/CDLI.10.5.780-786.2003
10.1017/S0950268812001689
10.1016/j.vaccine.2007.04.050
10.1016/S0008-6215(96)00253-4
10.1086/648963
10.2147/IDR.S21545
ContentType Journal Article
Copyright Copyright © 2013, American Society for Microbiology. All Rights Reserved. 2013 American Society for Microbiology
Copyright_xml – notice: Copyright © 2013, American Society for Microbiology. All Rights Reserved. 2013 American Society for Microbiology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7T5
H94
5PM
DOI 10.1128/CVI.00162-13
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Immunology Abstracts
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
DatabaseTitleList MEDLINE


MEDLINE - Academic
CrossRef
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1556-679X
EndPage 1507
ExternalDocumentID PMC3807210
23885033
10_1128_CVI_00162_13
cdli_20_10_1499
Genre Clinical Trial, Phase III
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.GJ
0R~
29B
2WC
39C
4.4
53G
5GY
5VS
AAFWJ
AAGFI
AAUOK
AAYXX
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
H13
HYE
HZ~
KQ8
O9-
RHI
RNS
RPM
RSF
TR2
W2D
W8F
WOQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7T5
H94
5PM
ID FETCH-LOGICAL-c445t-b4878d9a987c8d7dafa9c6ba0b136286122800030cb7bebc033286ce03ae663d3
ISSN 1556-6811
1556-679X
IngestDate Thu Aug 21 13:58:49 EDT 2025
Fri Jul 11 01:55:31 EDT 2025
Fri Jul 11 09:21:43 EDT 2025
Mon Jul 21 05:14:32 EDT 2025
Tue Jul 01 03:05:49 EDT 2025
Thu Apr 24 23:09:15 EDT 2025
Wed May 18 15:27:12 EDT 2016
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License The authors have paid a fee to allow immediate free access to this article.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c445t-b4878d9a987c8d7dafa9c6ba0b136286122800030cb7bebc033286ce03ae663d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ObjectType-Article-2
ObjectType-Feature-1
OpenAccessLink https://cvi.asm.org/content/cdli/20/10/1499.full.pdf
PMID 23885033
PQID 1437583523
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3807210
proquest_miscellaneous_1443376153
proquest_miscellaneous_1437583523
highwire_asm_cdli_20_10_1499
crossref_primary_10_1128_CVI_00162_13
crossref_citationtrail_10_1128_CVI_00162_13
pubmed_primary_23885033
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20131001
2013-10-00
2013-Oct
PublicationDateYYYYMMDD 2013-10-01
PublicationDate_xml – month: 10
  year: 2013
  text: 20131001
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Clinical and Vaccine Immunology
PublicationTitleAlternate Clin Vaccine Immunol
PublicationYear 2013
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_3_16_2
e_1_3_3_18_2
e_1_3_3_39_2
e_1_3_3_12_2
e_1_3_3_14_2
e_1_3_3_35_2
e_1_3_3_33_2
e_1_3_3_10_2
e_1_3_3_31_2
e_1_3_3_40_2
Australian Government Department of Health and Ageing (e_1_3_3_24_2) 2011
Lee B (e_1_3_3_27_2) 2012
e_1_3_3_5_2
e_1_3_3_7_2
e_1_3_3_9_2
Australian Government Department of Health and Ageing (e_1_3_3_28_2) 2010
e_1_3_3_29_2
e_1_3_3_48_2
e_1_3_3_25_2
e_1_3_3_46_2
e_1_3_3_44_2
e_1_3_3_3_2
e_1_3_3_21_2
e_1_3_3_42_2
Wassilak SG (e_1_3_3_50_2) 2004
Dbaibo G (e_1_3_3_37_2) 2012; 8
e_1_3_3_17_2
e_1_3_3_19_2
e_1_3_3_13_2
e_1_3_3_36_2
e_1_3_3_15_2
e_1_3_3_34_2
e_1_3_3_11_2
e_1_3_3_30_2
Centers for Disease Control and Prevention (e_1_3_3_22_2) 2011; 60
Sanofi Pasteur (e_1_3_3_23_2) 2011
e_1_3_3_6_2
Lechevin I (e_1_3_3_38_2) 2012
e_1_3_3_8_2
Centers for Disease Control and Prevention (e_1_3_3_32_2) 2006; 55
e_1_3_3_49_2
e_1_3_3_47_2
e_1_3_3_26_2
e_1_3_3_45_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_43_2
e_1_3_3_4_2
e_1_3_3_41_2
19357205 - J Clin Microbiol. 2009 Jun;47(6):1979-80
22038849 - Clin Vaccine Immunol. 2011 Dec;18(12):2038-42
22952888 - PLoS One. 2012;7(8):e44102
22704725 - Int J Infect Dis. 2012 Aug;16(8):e608-15
17532101 - Vaccine. 2007 Sep 3;25 Suppl 1:A101-7
408435 - J Infect Dis. 1977 Aug;136 Suppl:S78-83
19895922 - Vaccine. 2010 Jan 8;28(3):657-63
4977281 - J Exp Med. 1969 Jun 1;129(6):1327-48
18271745 - J Infect Dis. 2008 Mar 1;197(5):737-43
20144015 - Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S37-44
22114508 - Infect Drug Resist. 2011;4:161-9
12447774 - J Infect Dis. 2002 Dec 15;186(12):1848-51
17669003 - Expert Rev Vaccines. 2007 Aug;6(4):485-9
18834910 - Vaccine. 2009 Jan 1;27(1):161-8
22877581 - Epidemiol Infect. 2013 Mar;141(3):447-58
19477562 - Vaccine. 2009 Jun 24;27 Suppl 2:B51-63
16203934 - Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13
16988640 - MMWR Morb Mortal Wkly Rep. 2006 Sep 22;55(37):1016-7
12965904 - Clin Diagn Lab Immunol. 2003 Sep;10(5):780-6
21993344 - MMWR Morb Mortal Wkly Rep. 2011 Oct 14;60(40):1391-2
21278617 - Pediatr Infect Dis J. 2011 Apr;30(4):e56-62
21162617 - Expert Rev Vaccines. 2011 Jan;10(1):21-33
20218857 - Expert Rev Vaccines. 2010 Mar;9(3):285-98
12065513 - Infect Immun. 2002 Jul;70(7):3707-13
21993636 - Methods Mol Biol. 2012;799:1-20
22107850 - Vaccine. 2012 Jan 17;30(4):774-83
21492496 - Epidemiol Infect. 2011 Jul;139(7):967-85
20795751 - BioDrugs. 2010 Oct 1;24(5):287-97
17184222 - Expert Rev Vaccines. 2006 Dec;5(6):851-7
11495619 - JAMA. 2001 Aug 8;286(6):694-9
16418528 - Clin Microbiol Rev. 2006 Jan;19(1):142-64
18181736 - Clin Infect Dis. 2008 Feb 1;46(3):377-86
15597069 - Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S274-9
22485050 - Hum Vaccin Immunother. 2012 Jul;8(7):873-80
19887137 - Vaccine. 2010 Jan 8;28(3):744-53
21200360 - Pediatr Infect Dis J. 2011 Mar;30(3):e41-8
21343698 - Hum Vaccin. 2011 Feb;7(2):239-47
17233633 - FEMS Microbiol Rev. 2007 Jan;31(1):3-14
15755600 - Vaccine. 2005 Mar 18;23(17-18):2222-7
19586827 - J Formos Med Assoc. 2009 Jul;108(7):539-47
9008844 - Carbohydr Res. 1996 Dec 24;296:83-96
19464092 - Vaccine. 2009 Jun 24;27 Suppl 2:B64-70
20410516 - N Engl J Med. 2010 Apr 22;362(16):1511-20
References_xml – ident: e_1_3_3_6_2
  doi: 10.1586/erv.10.3
– ident: e_1_3_3_39_2
  doi: 10.1086/345763
– ident: e_1_3_3_49_2
  doi: 10.1001/archpedi.159.10.907
– ident: e_1_3_3_15_2
  doi: 10.1017/S0950268811000574
– ident: e_1_3_3_21_2
  doi: 10.1086/527401
– ident: e_1_3_3_35_2
  doi: 10.1016/j.ijid.2012.04.006
– ident: e_1_3_3_29_2
  doi: 10.1128/IAI.70.7.3707-3713.2002
– ident: e_1_3_3_33_2
  doi: 10.1093/infdis/136.Supplement.S78
– ident: e_1_3_3_3_2
  doi: 10.1016/j.vaccine.2009.04.063
– ident: e_1_3_3_45_2
  doi: 10.4161/hv.7.2.14068
– start-page: 145
  volume-title: Identification of key parameters that impact the sensitivity of the MenC-rSBA assay to natural antibodies
  year: 2012
  ident: e_1_3_3_38_2
– ident: e_1_3_3_17_2
  doi: 10.1128/CMR.19.1.142-164.2006
– ident: e_1_3_3_12_2
  doi: 10.1128/JCM.02390-08
– ident: e_1_3_3_43_2
  doi: 10.1097/INF.0b013e3182054ab9
– volume: 55
  start-page: 1016
  year: 2006
  ident: e_1_3_3_32_2
  article-title: Inadvertent misadministration of meningococcal conjugate vaccine: United States, June–August 2005
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
– ident: e_1_3_3_44_2
  doi: 10.1016/j.vaccine.2011.11.051
– ident: e_1_3_3_4_2
  doi: 10.1097/01.inf.0000147642.85129.05
– volume: 60
  start-page: 1391
  year: 2011
  ident: e_1_3_3_22_2
  article-title: Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
– ident: e_1_3_3_47_2
  doi: 10.1097/INF.0b013e31820e6e02
– volume: 8
  start-page: 873
  year: 2012
  ident: e_1_3_3_37_2
  article-title: The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.4161/hv.20211
– ident: e_1_3_3_48_2
  doi: 10.1016/j.vaccine.2009.10.104
– ident: e_1_3_3_26_2
  doi: 10.2165/11204790-000000000-00000
– ident: e_1_3_3_13_2
  doi: 10.1086/525260
– ident: e_1_3_3_7_2
  doi: 10.1001/jama.286.6.694
– ident: e_1_3_3_10_2
  doi: 10.1016/j.vaccine.2009.04.061
– ident: e_1_3_3_46_2
  doi: 10.1016/j.vaccine.2009.10.064
– volume-title: Australian public assessment report for groups A, C, Y and W-135 meningococcal polysaccharide diphtheria toxoid conjugate vaccine
  year: 2011
  ident: e_1_3_3_24_2
– start-page: 766
  volume-title: Vaccines
  year: 2004
  ident: e_1_3_3_50_2
– ident: e_1_3_3_36_2
  doi: 10.1016/j.vaccine.2008.08.075
– ident: e_1_3_3_41_2
  doi: 10.1084/jem.129.6.1327
– volume-title: Meningococcal vaccines
  year: 2012
  ident: e_1_3_3_27_2
– ident: e_1_3_3_19_2
  doi: 10.1586/14760584.5.6.851
– ident: e_1_3_3_9_2
  doi: 10.1111/j.1574-6976.2006.00051.x
– volume-title: Australian public assessment report for meningococcal conjugated vaccine
  year: 2010
  ident: e_1_3_3_28_2
– ident: e_1_3_3_16_2
  doi: 10.1016/S0929-6646(09)60371-5
– ident: e_1_3_3_11_2
  doi: 10.1056/NEJMra0906357
– ident: e_1_3_3_20_2
  doi: 10.1128/CVI.05354-11
– ident: e_1_3_3_25_2
  doi: 10.1586/erv.10.147
– ident: e_1_3_3_5_2
  doi: 10.1007/978-1-61779-346-2_1
– ident: e_1_3_3_42_2
  doi: 10.1371/journal.pone.0044102
– ident: e_1_3_3_31_2
  doi: 10.1016/j.vaccine.2005.01.051
– ident: e_1_3_3_2_2
  doi: 10.1586/14760584.6.4.485
– ident: e_1_3_3_30_2
  doi: 10.1128/CDLI.10.5.780-786.2003
– ident: e_1_3_3_14_2
  doi: 10.1017/S0950268812001689
– ident: e_1_3_3_40_2
  doi: 10.1016/j.vaccine.2007.04.050
– ident: e_1_3_3_34_2
  doi: 10.1016/S0008-6215(96)00253-4
– ident: e_1_3_3_8_2
  doi: 10.1086/648963
– ident: e_1_3_3_18_2
  doi: 10.2147/IDR.S21545
– volume-title: Menactra (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine) prescribing information
  year: 2011
  ident: e_1_3_3_23_2
– reference: 18271745 - J Infect Dis. 2008 Mar 1;197(5):737-43
– reference: 20218857 - Expert Rev Vaccines. 2010 Mar;9(3):285-98
– reference: 17184222 - Expert Rev Vaccines. 2006 Dec;5(6):851-7
– reference: 21278617 - Pediatr Infect Dis J. 2011 Apr;30(4):e56-62
– reference: 22704725 - Int J Infect Dis. 2012 Aug;16(8):e608-15
– reference: 22114508 - Infect Drug Resist. 2011;4:161-9
– reference: 21993344 - MMWR Morb Mortal Wkly Rep. 2011 Oct 14;60(40):1391-2
– reference: 408435 - J Infect Dis. 1977 Aug;136 Suppl:S78-83
– reference: 18181736 - Clin Infect Dis. 2008 Feb 1;46(3):377-86
– reference: 21492496 - Epidemiol Infect. 2011 Jul;139(7):967-85
– reference: 21343698 - Hum Vaccin. 2011 Feb;7(2):239-47
– reference: 12065513 - Infect Immun. 2002 Jul;70(7):3707-13
– reference: 21993636 - Methods Mol Biol. 2012;799:1-20
– reference: 22952888 - PLoS One. 2012;7(8):e44102
– reference: 17532101 - Vaccine. 2007 Sep 3;25 Suppl 1:A101-7
– reference: 16418528 - Clin Microbiol Rev. 2006 Jan;19(1):142-64
– reference: 16988640 - MMWR Morb Mortal Wkly Rep. 2006 Sep 22;55(37):1016-7
– reference: 20410516 - N Engl J Med. 2010 Apr 22;362(16):1511-20
– reference: 19586827 - J Formos Med Assoc. 2009 Jul;108(7):539-47
– reference: 22038849 - Clin Vaccine Immunol. 2011 Dec;18(12):2038-42
– reference: 19887137 - Vaccine. 2010 Jan 8;28(3):744-53
– reference: 22107850 - Vaccine. 2012 Jan 17;30(4):774-83
– reference: 18834910 - Vaccine. 2009 Jan 1;27(1):161-8
– reference: 11495619 - JAMA. 2001 Aug 8;286(6):694-9
– reference: 20144015 - Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S37-44
– reference: 22485050 - Hum Vaccin Immunother. 2012 Jul;8(7):873-80
– reference: 19464092 - Vaccine. 2009 Jun 24;27 Suppl 2:B64-70
– reference: 12447774 - J Infect Dis. 2002 Dec 15;186(12):1848-51
– reference: 17669003 - Expert Rev Vaccines. 2007 Aug;6(4):485-9
– reference: 20795751 - BioDrugs. 2010 Oct 1;24(5):287-97
– reference: 4977281 - J Exp Med. 1969 Jun 1;129(6):1327-48
– reference: 15597069 - Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S274-9
– reference: 19895922 - Vaccine. 2010 Jan 8;28(3):657-63
– reference: 22877581 - Epidemiol Infect. 2013 Mar;141(3):447-58
– reference: 19357205 - J Clin Microbiol. 2009 Jun;47(6):1979-80
– reference: 16203934 - Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13
– reference: 21162617 - Expert Rev Vaccines. 2011 Jan;10(1):21-33
– reference: 17233633 - FEMS Microbiol Rev. 2007 Jan;31(1):3-14
– reference: 15755600 - Vaccine. 2005 Mar 18;23(17-18):2222-7
– reference: 21200360 - Pediatr Infect Dis J. 2011 Mar;30(3):e41-8
– reference: 12965904 - Clin Diagn Lab Immunol. 2003 Sep;10(5):780-6
– reference: 19477562 - Vaccine. 2009 Jun 24;27 Suppl 2:B51-63
– reference: 9008844 - Carbohydr Res. 1996 Dec 24;296:83-96
SSID ssj0043687
Score 2.147929
Snippet OA  Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley...
In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A...
SourceID pubmedcentral
proquest
pubmed
crossref
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1499
SubjectTerms Acetylation
Adolescent
Adult
Blood Bactericidal Activity
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - pathology
Fatigue
Fatigue - epidemiology
Female
Headache - epidemiology
Healthy Volunteers
Humans
Male
Meningococcal Vaccines - administration & dosage
Meningococcal Vaccines - adverse effects
Meningococcal Vaccines - immunology
Neisseria meningitidis
Pain - epidemiology
Polysaccharides, Bacterial - immunology
Polysaccharides, Bacterial - metabolism
Vaccines
Vaccines, Conjugate - administration & dosage
Vaccines, Conjugate - adverse effects
Vaccines, Conjugate - immunology
Young Adult
Title Meningococcal Polysaccharide A O-Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years
URI http://cvi.asm.org/content/20/10/1499.abstract
https://www.ncbi.nlm.nih.gov/pubmed/23885033
https://www.proquest.com/docview/1437583523
https://www.proquest.com/docview/1443376153
https://pubmed.ncbi.nlm.nih.gov/PMC3807210
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGEIgXBOOrMJCR4CkE8p2Ut6oDrbCOAh0aT5HjuFtYm1RNguj-bv4A7uwkTdBAsJeqctxc0ruf786-D0KecTQSbGborik83ZmZtt63I1vH0uMzW4jAi_FEd3zo7R85747d460rvBW1VBbRS35-YV7JZbgKY8BXzJL9D842N4UB-A78hU_gMHz-E4_HAnc1MljT8J-eZPN1zjjmUSWxAMR_0AdcFGsV7aYdYHhQDhazdpgVWBUYsyNl7CSmiGRAJOFVfAaOfixZvErgaTFYoEtoKsCiLHNtmv3IkhiTBr-VuBunfQHqWLhUBtnl5bzIVfoK0z6xNM4WybnaWh2q-Pg5GLuTU1Cj2mg0khGNkrrKjFprg1jeYXAC08wAjWTL1b4CMvO2RT2sUzvxBOC7egAtka_UPjA4KJdJXm32wnusVllzJVmc4TnNWTmvVj2RnuSsyWD6nOXSwD4UVWXmOhwiLU4Z-CGJaqY1yVYwIJbtbRRzE5BXtDIXcEltBcuOk00xrLaOcD3dCyodIVpjvuwK3CgWy2gDyGipCXBL-y2TA43yi9WZhSkawy8jPDDzLF2l7bYke7mQog12V4Dn0Rul3oRaTsZD7ClgYRriVQt8KdRee6P3tbmCHQhkB6L6rersECt41SaMVbMrKl0Tri6rfZGL9nukcct0m94iNyufiw4UgG6TLZHukGuqC-t6h1wfV_Eld8jPjqDTLqLogHYQRRWi6F5GAVFUIYqCDNAuomg2k6NtRNEuoQpRVCGKNoiiFaJe0wpPFPFEGd3g6QXdoIlKNFFAE5VoQsoVmqhCE0U0UTOgRUYtl0o03SVHb99Mh_t61RdF547jFnrkBH4Q91k_8HkQ-zGbsT73ImZEpo2Z5iaWuELtzSM_EhEHlsEoNgZkAhyM2L5HttMsFQ8I7XvcBB9L2J7gzszxInAAjJnrz1wzjgzm9IhWszrkVdMA7F0zD-XmgRWEICOhlJHQtHvkeTN7qYrl_GHebi01IcsXIY_nSWgZci4go0ee1pIUgrLDE0yWiqzM4artu-gz2n-b49hgNYEl1yP3lfQ1D1NLcI_4HblsJmCx_e6VNDmVRfcrED289C8fkRubdWeXbBerUjwGh6aInkhA_gLkQlV0
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Meningococcal+Polysaccharide+A+O-Acetylation+Levels+Do+Not+Impact+the+Immunogenicity+of+the+Quadrivalent+Meningococcal+Tetanus+Toxoid+Conjugate+Vaccine%3A+Results+from+a+Randomized%2C+Controlled+Phase+III+Study+of+Healthy+Adults+Aged+18+to+25+Years&rft.jtitle=Clinical+and+vaccine+immunology&rft.au=Lupisan%2C+Socorro&rft.au=Limkittikul%2C+Kriengsak&rft.au=Sosa%2C+Nestor&rft.au=Chanthavanich%2C+Pornthep&rft.date=2013-10-01&rft.pub=American+Society+for+Microbiology&rft.issn=1556-6811&rft.eissn=1556-679X&rft.volume=20&rft.issue=10&rft.spage=1499&rft.epage=1507&rft_id=info:doi/10.1128%2FCVI.00162-13&rft_id=info%3Apmid%2F23885033&rft.externalDocID=PMC3807210
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-6811&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-6811&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-6811&client=summon